Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: A phase II southwest oncology group study (S0415)

Journal of Thoracic Oncology

Volumn 5, Issue 9, 2010, Pages 1472-1476

  Gold, Philip J ^a   Goldman, Bryan ^b   Iqbal, Syma ^c   Leichman, Lawrence P ^d   Zhang, Wu ^c   Lenz, Heinz Josef ^c   Blanke, Charles D ^e  

^a SWEDISH MEDICAL CENTER   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d DESERT REGIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cetuximab; Esophageal cancer; Second line therapy

Indexed keywords

CETUXIMAB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 8; K RAS PROTEIN; NEUROPILIN 1; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS METASTASIS; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; LOADING DRUG DOSE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN DISEASE; TREATMENT RESPONSE;

EID: 77956267602     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e77a92     Document Type: Article

References (25)

1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta, GA: American Cancer Society; 2009. Pp. 4.
2. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
3. Ajani JA, Baker J, Pisters PW, et al. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology 2002; 16:16-18.
4. Chau I, Norman AR, Ross J, et al. Multivariate prognostic factor analysis and second line treatment in locally advanced and metastatic oesophago-gastric cancer: pooled analysis of 1,080 patients from three multicentre randomized controlled trials using individual patient data. Proc Am Soc Clin Oncol Gastrointest Cancer Sympos 2004: Abstract #5.
5. Thuss-Patience PC, Kretzschmar A, Deist T, et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2009;27:15S (Suppl; Abstract 4540).
6. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Ann Rev Biochem 1988;57:443-478.
7. Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327-1333.
8. Yacoub I, Goldman H, Odze RD. Transforming growth factor-alpha, epidermal growth factor receptor and MiB-1 expression in Barrett's associated neoplasia: correlation with prognosis. Mod Pathol 1997;10: 105-112.
9. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-1318.
10. Waksal HW. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 1999;18:427-436.
11. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003;22:1012a.
12. Figlin R, Belldegrun, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase I clinical results. Proc Am Soc Clin Oncol 2002;21:35.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;52:457-481.
14. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208.
15. Saltz L, Rubin MS, Hochster HS, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer that expresses epidermal growth factor receptor. Proc Am Soc Clin Oncol 2001;20:3a.
16. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
17. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007;18:510-517.
18. Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesphageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009;101:1261-1268.
19. Van Cutsem E, Mayer RJ, Gold P, et al. Correlation of acne skin rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Eur J Cancer 2004;85(Suppl 2):Abstract 279.
20. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-4921.
21. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
22. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fuorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009; 20:1667-1673.
23. Stella G, Rojas Llimpe FL, Barone C, et al. KRAS and BRAF mutational status and response to cetuximab combination therapy in advanced gastric cancer (GC) patients. Proc Am Soc Clin Oncol Gastrointest Cancer Sympos 2009: Abstract #34.
24. Hecht JR, Mitchell EP, Baranda J, et al. Panitumumab (pmab) efficacy in patients (pts) with metastatic colorectal cancer (mCRC) with low or undetectable levels of epidermal growth factor receptor (EGFr): Final efficacy and KRAS analyses. Proc Am Soc Clin Oncol Gastrointest Cancer Sympos 2008: Abstract #343.
25. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-572.